RxDoctor Payments Data

Conrad Nievera, MD

Clinical Neurophysiology · Spokane, WANPI 1346292018

Payments from drug & device makers

$66,984in general payments, 2019–2025

Across 328 payments — averaging $204.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • SK Life Science, Inc.$43K
  • Supernus Pharmaceuticals, Inc.$10K
  • Livanova USA, Inc.$5K
  • Jazz Pharmaceuticals Inc.$868
  • Sanofi$847
  • Greenwich Biosciences, Inc.$720
  • plus $7K from 40 others

What the payments were for

  • Consulting fees$8604%
  • Speaking & faculty fees$8,52635%
  • Travel & lodging$5,24922%
  • Food & beverage$9,49239%
  • Education$1721%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few clinical neurophysiology providers in Washingtonto place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$30,227
Medicare patients
244
Services billed
395

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EpidiolexCannabidiol (Cbd)105$403,088
FycompaPerampanel72$81,838
BriviactBrivaracetam33$49,300
Lacosamide212$43,763
ZonisadeZonisamide22$40,335
XcopriCenobamate39$38,125
Nurtec OdtRimegepant Sulfate14$26,205
Levetiracetam762$25,136
VimpatLacosamide25$23,895
Keppra XrLevetiracetam12$19,039
NayzilamMidazolam17$10,916
Lamotrigine648$10,692
Clobazam64$10,413
Emgality PenGalcanezumab-Gnlm12$9,238
Oxcarbazepine119$9,231

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
UCB, Inc.Briviact, Vimpat, Nayzilam$215$84,11175 claims
Eisai Inc.Fycompa$326$81,83872 claims
SK Life Science, Inc.Xcopri$43,060$38,12539 claims
Upsher-smith Laboratories LLCTopiramate$23$1,459127 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few clinical neurophysiology providers in Washingtonon file to place this against a meaningful peer group, so we don't.

Other clinical neurophysiology in Spokane

Where these figures come from

Is this you, or does something look wrong? →